Private Equity Interest CVC Capital Partners has invested $77.8M, signaling strong financial backing and potential for strategic partnerships. Engage on growth rounds or co-investment opportunities to expand distribution, manufacturing capacity, and regional reach.

Global Expansion Recent and ongoing international activities include a Switzerland subsidiary and partnerships with global players like Fujirebio, Mindray, and I-Sens. Explore CDMO collaboration, OEM opportunities, and cross-border distribution deals to broaden market access.

Clinical TB & AD Opportunities Recent collaborations and R&D efforts in TB screening and Alzheimer's disease biomarkers present entry points for diagnostic reagents, automated analyzers, and specialized kits. Propose integrated reagent ecosystems and compatible instrumentation bundles.

COVID & Molecular Diagnostics Past launches of RT-LAMP and RNA extraction kits demonstrate agility in infectious disease solutions. Identify demand for scalable RT-LAMP workflows, confirmatory testing solutions, and expansion of point-of-care molecular offerings in emerging markets.

Compliance & Quality ISO 9001 and ISO 13485, GMP conformity, and FDA-approved facilities underscore reliability and regulatory readiness. Position premium-grade reagents and fully automated analyzers to regional labs and hospital networks seeking compliant, end-to-end DIAGNOSTIC solutions.